Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)

NCT02471716 is registered in ClinicalTrials.gov with Five Prime Therapeutics, Inc. as lead sponsor.

NCT NCT02471716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02471716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
Lead sponsor
Five Prime Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2015
Completion date
April 30, 2020
Enrollment
66 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pigmented villonodular synovitis, tenosynovial giant cell tumor